Targeting poor proteasomal function with radioiodine eliminates CT26 colon cancer stem cells resistant to bortezomib therapy

Jin Hee Lee1,2, Kyung-Ho Jung1,2, Jin Won Park3, Seung Hwan Moon1, Young Seok Cho1 & Kyung-Han Lee1,2*

We tested the hypothesis that tumor response to conventional bortezomib (BTZ) treatment is enhanced by targeted radiotherapy of resistant cancer stem cells (CSCs) that have characteristically poor proteasome function. This was accomplished by augmenting 131I uptake through expression of a sodium-iodide symporter (NIS) fusion protein that accumulates in cells with low proteasome activity. The NIS gene fused with the C-terminal of ornithine decarboxylase degron (NIS-cODC) was cloned. Stably expressing CT26/NIS-cODC cells and tumorsphere-derived CSCs were evaluated for NIS expression and radioiodine uptake. CT26/NIS-cODC cells implanted into mice underwent PET imaging, and tumor-bearing mice were treated with BTZ alone or with BTZ plus 131I. CT26/NIS-cODC cells accumulated NIS protein, which led to high radioiodine uptake when proteasome activity was inhibited or after enrichment for stemness. The cell population that survived BTZ treatment was enriched with CSCs that were susceptible to 131I treatment, which suppressed stemness features. Positron emission tomography and uptake measurements confirmed high 124I and 131I uptake of CT26/NIS-cODC CSCs implanted in living mice. In CT26/NIS-cODC tumor-bearing mice, whereas BTZ treatment modestly retarded tumor growth and increased stemness markers, combining 131I therapy suppressed stemness features and achieved greater antitumor effects. The NIS-cODC system offers radioiodine-targeted elimination of CSCs that are tolerant to proteasome inhibition therapy.

A major challenge in cytotoxic cancer therapies is that not all tumor cells demonstrate equivalent sensitivity. Therefore, after cytotoxic drugs succeed in eliminating the bulk of the tumor, the limit of their effectiveness is met, and the surviving population propagates to drive cancer relapse1. Crucial contributors to this phenomenon are cancer cells with stemness properties that have preferential resistance to chemotherapeutics2,3. Tumor relapse occurs through pre-existing resistant clones4-6, although oncogenic mutations induced by the cytotoxic agents might also contribute7. The recognition of a special tumor cell population that shares characteristics with normal stem cells is changing our perspective of cancer therapy8. These cancer stem cells (CSCs) are resistant to a variety of chemotherapeutics and have the capacity to self-renew and differentiate into all tumor cell types during relapse2. Therefore, improvement in cancer therapy crucially requires novel techniques that specifically target treatment-tolerant CSCs.

An emerging strategy in anticancer drug development is targeting essential tumor-supportive cellular machinery9, which includes regulations of division rate, transporter expression, and proteasomal activity. Differentiated tumor cells have high proteasome activity10,11, to help eliminate onco-suppressive proteins12, which is exploited by pharmacological proteasome inhibition for treatment13,14. Indeed, the proteasome inhibitor...
bortezomib (BTZ) has shown encouraging results in treating multiple myeloma and mantle cell lymphoma\textsuperscript{15,16}. However, the clinical efficacy of proteasome inhibitors to treat solid tumors has been disappointing thus far\textsuperscript{17}. A previous study showed that proteasome inhibitors can destroy the bulk of a tumor, but they cannot eliminate drug-resistant CSCs that exhibit self-renewal\textsuperscript{18}. In contrast to the bulk of tumor cells, CSCs, which have the capacity to propagate tumors and resist treatment, have poor proteasome function\textsuperscript{19–25}. Downregulated proteasome activity could be a prerequisite for stabilizing the proteins required to maintain stem cell traits in these cells. In other words, BTZ can eliminate the bulk of tumor cells, which depend on high proteasome activity, but the surviving portion is likely to be composed of CSCs with poor proteasome function. New strategies to eliminate treatment-resistant cells are therefore needed to improve the efficacy of proteasome inhibitors, and a unique opportunity may be provided by eroding the advantages of perturbed proteasome function.

Our group recently demonstrated that the sodium iodine symporter (NIS) fused to the C-terminus of the ornithine decarboxylase (cODC) degron (NIS-cODC) instigates high levels of radioiodine uptake into cancer cells under proteasome suppression\textsuperscript{26}. In this study, we hypothesized that the NIS-cODC system could be implemented to enable \textsuperscript{131}I-based therapeutic elimination of CSCs that contribute to resistance to BTZ treatment.

Results
CT26/NIS-cODC cells accumulate NIS and take up radioiodine under proteasome inhibition. The proteasome activity of CT26 cells that constitutively overexpress NIS-cODC (CT26/NIS-cODC cells) was completely suppressed in the presence of 100 nM BTZ (Fig. 1A). In these cells, NIS protein was undetectable at baseline but markedly increased to 63.9 ± 4.4-fold of controls under BTZ exposure (P < 0.005; Fig. 1B). This contrasted with CT26 cells, wherein NIS expression was undetectable regardless of BTZ exposure (Fig. 1B). Similarly, \textsuperscript{125}I uptake was low in CT26/NIS-cODC cells at baseline but was substantially increased to 332.0 ± 29.8% of controls in the presence of BTZ (P < 0.001; Fig. 1B).

CT26/NIS-cODC cells enriched for stemness accumulate NIS and have high radioiodine uptake. CT26/NIS-cODC cells efficiently formed tumorspheres after 10 days of culture on an ultra-low attachment plate in CSC selection medium (Fig. 2A). Tumorspheres of CT26 cells that constitutively express ZsGreen-cODC (CT26/ZsGreen-cODC cells) were highly fluorescent in the absence of BTZ, indicating inherently low proteasome activity (Fig. 2A). Tumorsphere-derived CT26/NIS-cODC cells displayed a complete abrogation of proteasome activity (Fig. 2B) and a 4.6 ± 0.1-fold increase of CD133 expression compared with monolayer-grown cells (P < 0.001; Fig. 2A), indicating enrichment for CSCs. These cells demonstrated a 59.0 ± 3.3-fold increase of NIS expression (P < 0.001; Fig. 2A) and high \textsuperscript{125}I uptake that reached 406.4 ± 24.5% of that of monolayer-grown control cells (P < 0.001; Fig. 2B). Furthermore, unlike monolayer-grown cells, the CSCs did not demonstrate a further increase of \textsuperscript{125}I uptake by BTZ exposure.

The lack of further increase of \textsuperscript{125}I uptake by BTZ treatment in tumorsphere-derived CT26/NIS-cODC cells is explained by their enrichment for CSCs, which have inherently low proteasome activity as confirmed in Fig. 2B. Low proteasome activity would suppress proteasomal degradation of cODC fused NIS protein, thereby negating any additional increase of NIS-cODC accumulation by the proteasome inhibitor BTZ. Hence, NIS-cODC accumulation and \textsuperscript{125}I uptake was high in CT26/NIS-cODC cells with little difference between baseline and after BTZ treatment.
CT26/NIS-cODC cell populations that survive BTZ treatment are enriched with CSCs. Survival of monolayer grown CT26/NIS-cODC cells was dose-dependently reduced by BTZ treatment, reaching 87.7 ± 0.7% and 67.9 ± 1.2% of the untreated level after 3 days of treatment with 25 nM and 50 nM BTZ, respectively. The half maximal inhibitory concentration (IC50) for BTZ was 91.6 nM (Fig. 3A). Cells that survived 7 days of treatment with 50 nM (freshly replaced every 2 days) were considered BTZ-resistant. When the cells tolerant to BTZ treatment were evaluated for stemness properties, western blots showed that CD133 expression was increased to 182.6 ± 8.8% of the baseline level (P < 0.001; Fig. 3B). In FACS assays, these cells showed a 2.7 ± 0.2-fold increase in Aldefluor positivity (P < 0.001) reaching 19.9 ± 1.4% from 7.5 ± 1.6% at baseline (Fig. 3B). In Efflux-ID Green assays, a slight left shift with a small increase of stain-negative cells was observed (1.2 ± 0.2% vs. 2.5 ± 0.3%, P = 0.004; Fig. 3C), indicating slightly greater MDR1-mediated dye efflux. Furthermore, limiting
dilution assays revealed that the number of tumorspheres formed from seeding 1,000 cells increased markedly, from 7.0 ± 0.8 to 27.2 ± 2.9 (P < 0.001; Fig. 3D). The minimum number of cells required for tumorsphere formation decreased from 100 cells for the untreated group to 10 cells for the BTZ-resistant group (Fig. 3D).

131I treatment augments the therapeutic efficacy of BTZ and suppresses cancer stemness. We next investigated whether 131I therapy would enhance tumor treatment by eliminating BTZ-tolerant CSCs. We first showed that 131I alone did not influence CT26/NIS-cODC cell survival (Fig. 4A). This is because without tumorsphere formation or BTZ treatment, CT26/NIS-cODC cells have high proteasome activity that does not allow NIS-cODC accumulation. Since the culture medium was changed to fresh media at 9 h after I-131 was added, the level of radiation delivered to the cell interior would have been quite limited without cellular 131I uptake through NIS.

In contrast, adding 131I to cells receiving BTZ treatment further suppressed survival in a dose-dependent manner. Thus, the surviving fraction that was decreased to 67.9 ± 1.3% of controls by 50 nM BTZ alone was further reduced to 47.3 ± 1.2% and 38.4 ± 0.7% of controls (both P < 0.001) by adding 50 and 100 μCi of 131I, respectively (Fig. 4B).

CD133 and ALDH3A1 expression increased slightly with BTZ treatment alone, to 131.2 ± 8.9% and 141.4 ± 2.5% of controls, respectively (Fig. 4C). However, when 131I was added to BTZ treatment, there were markedly reductions of CD133 protein to 26.7 ± 4.0%; ALDH3A1 protein to 36.3 ± 7.4%; and SOX2 protein to 20.2 ± 2.8% of controls (Fig. 4C).
CT26/NIS-cODC cells enriched for stemness have high radioiodine uptake in vivo. Prior to tumor model experiments, we confirmed that tumorsphere-derived CSCs have increased radioiodine uptake in living bodies. This was accomplished by implanting the cells into thighs of normal mice followed by intravenous 124I injection and positron emission tomography/computed tomography (PET/CT) imaging. The resulting images displayed focal increased radioiodine uptake in regions containing tumorsphere-derived CT26/NIS-cODC CSCs but not in regions with monolayer-grown CT26/NIS-cODC cells (Fig. 5A). Immunohistochemistry confirmed abundance of cancer cells staining strongly positive for NIS protein in the former but not in the latter tissues (Fig. 5A). Region-of-interest analysis confirmed greater target-to-background count ratios for regions containing CSCs compared with those containing monolayer-grown cells (1.78 ± 0.17 vs. 1.09 ± 0.19; P < 0.01; Fig. 5B). Ex vivo measured radioactivity counts accredited to the implanted cells showed similar results (438.1 ± 118.7% vs. 100.0 ± 45.0%; P < 0.01), and linear regression analysis verified that the PET-based in vivo measurements reliably assessed the level of radioiodine uptake by the implanted cells (Fig. 5B).

Repeat experiments in a separate group of mice using 131I instead of 124I demonstrated that ex vivo 131I counts accredited to the implanted cells was significantly higher at 357.9 ± 134.8% for regions containing tumorsphere-derived CT26/NIS-cODC CSCs compared to regions containing monolayer-grown CT26/NIS-cODC cells (P < 0.01). This result is highly consistent with that obtained using 124I.
131I therapy potentiates the efficacy of BTZ treatment against CT26/NIS-cODC tumors. When mice were treated with BTZ alone, non-transformed CT26 tumors responded with a slight retardation of growth with a tumor volume of $2,953.4 \pm 944.0 \text{mm}^3$ by day 18 compared to $3,661.2 \pm 590.0 \text{mm}^3$ for controls (Fig. 6A).
In these animals, adding a single intravenous dose of $^{131}$I at 7 days of BTZ treatment did not further reduce tumor size ($2,613.9 \pm 517.8 \text{ mm}^3$; Fig. 6A).

In mice bearing CT26/NIS-cODC tumors, treatment with $^{131}$I alone for 28 days did not reduce tumor size compared to that of control mice. Treatment with BTZ alone for 28 days decreased the tumor to $3,235.0 \pm 678.2 \text{ mm}^3$, compared with $6,234.7 \pm 2,113.5 \text{ mm}^3$ for the controls ($P<0.005$; Fig. 6B). In these animals, a single intravenous dose of $^{131}$I in addition to BTZ further suppressed tumor volume to $1,212.8 \pm 848.2 \text{ mm}^3$ on day 28 ($P<0.001$ compared to the BTZ alone; Fig. 6B). Body weight at the end of treatment did not differ between the CT26 tumor-bearing groups and was slightly lower in the BTZ plus $^{131}$I group for CT26/NIS-cODC tumor-bearing mice (Fig. 6A,B).

Cancer stemness in vivo is increased by BTZ alone but is suppressed by combining $^{131}$I therapy. Evaluation of cancer stemness properties in residual tumor tissue after treatment with BTZ alone revealed increased CD133 expression to $188.7 \pm 26.7\%$ ($P<0.001$) and ALDH3A1 expression to $146.5 \pm 24.7\%$ of controls ($P<0.005$; Fig. 6C). However, a single intravenous dose of $^{131}$I in addition to BTZ significantly decreased these stemness markers. Hence, CD133 expression was suppressed from $188.7 \pm 26.7\%$ to $48.4 \pm 21.4\%$ of controls ($P<0.001$) and ALDH3A1 expression was suppressed from $146.5 \pm 24.7\%$ to $72.2 \pm 10.6\%$ of controls ($P<0.001$; Fig. 6C).

Discussion
Treatment resistance remains a serious limitation to our ability to conquer colon cancer. Colon tumors contain individual cancer cells that display variable tolerance to chemotherapeutic agents. Hence, initially minor clones that have greater tolerance to the drugs become dominant and promote tumor regrowth. The functional heterogeneity of colon cancers is principally determined by a distinct population of cells with stemness properties. Thus, any strategy to cure colon cancer will require a method for specific targeting and the elimination of drug-resistant CSCs.

CSCs differ from the bulk of differentiated cancer cells that have high proteasome activity by having inherently poor proteasome function. This is demonstrated in living cells by specialized protein sequences that are recognized by the proteasomal system for elimination. An example is the well-established cODC degron that undergoes rapid ubiquitin-independent proteasomal degradation. Therefore, cODC sequence-fused proteins are promptly destroyed in cells with normal proteasomal activity but are stable and accumulate in cells with poor proteasome function. In a pioneering work, Vlashi and coworkers constructed and stably expressed a ZsGreen-cODC fusion gene in glioma and breast cancer cells. Increased fluorescent signals allowed the in vitro identification and in vivo tracking of CSCs. The construct also identified CSCs originating from the pancreas, prostate, brain, head and neck, cervix, and lung. Furthermore, the construct showed that breast cancer cells with low proteasome activity produced larger tumors and had more metastatic spread in mice.

In this study, we linked the cODC sequence to the NIS gene to produce a fusion protein that accumulates under poor proteasome function and promotes the intracellular transport of radioiodine for targeted CSC therapy. Blocking proteasome activity of CT26 colon cancer cells stably expressing the NIS-cODC construct resulted in substantial accumulation of NIS protein that was undetectable at baseline because they underwent proteasomal degradation. Our group previously showed that this property of the NIS-cODC system can be exploited for imaging of CT26 tumors under proteasomal inhibition with $^{124}$I PET. In the present study, CT26 CSCs were found to have intrinsically low proteasome activity even at baseline. Several malignancies harbor a small subset of CSCs with low proteasomal activity, and possible mechanistic links have been identified. CT26/ZsGreen-cODC cells in tumorspheres showed high fluorescence and CT26/NIS-cODC CSCs from tumorspheres showed high NIS protein accumulation. The latter cells had high radiiodine uptake at baseline that was even greater than that of monolayer grown cells under proteasomal suppression. These results confirm that CT26/NIS-cODC CSCs have high radiiodine-avidity due to inherently poor proteasome function.

When CT26/NIS-cODC cells were treated with BTZ for a week, most of the cells were eradicated but there was a small population that remained viable. This is consistent with the notion that cancer cells with low proteasome activity have a propensity to survive treatment and subsequently drive tumor regrowth. For instance, ZsGreen-cODC expression from low proteasome activity has been associated with treatment resistance in malignant cells of the prostate, cervix, bone, and head and neck. Recently, colorectal cancer cells displaying low proteasome activity were associated with stem-like properties and radio-chemoresistance. The link between poor proteasome activity and treatment resistance extends to responses to BTZ, which was previously demonstrated in head and neck and papillary thyroid CSCs. Also, a new-generation proteasome inhibitor called NPI-0052 failed to eradicate the CSC population in glioblastoma xenografts. Furthermore, lymphoma cells with stemness properties resisted BTZ treatment, whereas the drug suppressed clonogenic activity after the cells had differentiated. Together, these findings indicate that CSCs contribute to BTZ resistance, presumably because they are less dependent on protein degradation for survival than differentiated cancer cells.

Cancer stemness require stabilization of proteins that regulate the pluripotency network. Slow protein turnover by proteasomal downregulation prevents the degradation of proteins required for stemness. In this study, CT26 cells that survived BTZ treatment displayed increased expression of CD133, a surface marker highly expressed on CSCs from various origins including colon cancer. BTZ-resistant CT26 cells also showed increased activity of ALDH, an intracellular detoxifying enzyme highly expressed in stem cells and CSCs. P-glycoprotein activity was only slightly increased in these cells, consistent with the notion that BTZ is a poor substrate for p-glycoprotein and that this transporter does not play a large role in BTZ resistance. Importantly, these cells displayed substantially greater tumorsphere-forming capacity. Together, these findings reveal that cancer cells that survive BTZ treatment are enriched with CSCs that have intrinsically poor proteasome function and are
insensitive to suppressed protein turnover. In addition to simply selecting for CSCs, proteasome inhibition might even contribute to the acquisition of this phenotype. This points to the importance of novel strategies to eliminate resistant CSCs for the success of proteasome inhibitor therapy.

Figure 6. $^{131}$I potentiates BTZ treatment efficacy and suppresses stemness in tumor-bearing mice. (A) Growth of CT26 tumors in mice treated with BTZ alone ($n = 4$) or BTZ plus $^{131}$I ($n = 4$) compared to vehicle-injected animals ($n = 3$). (B) Growth of CT26/NIS-cODC tumors in mice treated with $^{131}$I alone ($n = 8$), BTZ alone ($n = 7$) or BTZ plus $^{131}$I ($n = 8$), compared to vehicle-injected animals ($n = 7$). The weights of mice after tumor removal are also shown. All data are the mean ± SD of tumor volume. $^* P < 0.005$, $^† P < 0.001$, compared to vehicle-treated controls. (C) Western blots for CD133 (left) and ALDH3A1 expression (right) in residual CT26/NIS-cODC tumors after treatment with vehicle ($n = 7$), BTZ ($n = 7$), or BTZ plus $^{131}$I ($n = 8$). Blots are cropped with single blot parts separated by space. For full length blot pictures, see supplement Fig. 5. Bars are the mean ± SD of % band intensities normalized to β-actin bands. $** P < 0.01$, $^† P < 0.005$, $^‡ P < 0.001$, compared to vehicle-treated controls. BTZ: bortezomib; ALDH3A1: Aldehyde dehydrogenase 3A1.
Perturbed proteasome function that contributes to proteasome inhibitor resistance also offers a unique and attractive opportunity to specifically eliminate treatment-resistant CSCs. As an example, CSCs that expressed the cODC degron fused to the thymidine kinase gene could be targeted by treatment with ganciclovir, which abrogated sphere formation in vitro and caused regression of xenotransplants in vivo. NIS, a selective transmembrane carrier for iodide, not only allows imaging via γ-emitting radioiodine but also allows the elimination of target cells via β-emitting 131I. NIS provides a versatile system for targeting cells in living bodies because it does not deter basic cell physiology or elicit an immune response in vivo. It is not a foreign protein but is normally expressed in only a few tissues. Furthermore, various radioiodine substrates for NIS-mediated uptake are already widely applied for clinical use and are readily available without any radiochemical synthesis.

In our in vitro experiments, treating CT26/NIS-cODC cells with 131I plus BTZ suppressed cell survival to a significantly greater degree than BTZ alone. Furthermore, the stemness markers ALDH3A1 and CD133 were increased by treatment with BTZ alone but were substantially decreased when 131I therapy was added. The stemness marker SOX2 was also substantially reduced by 131I plus BTZ treatment. These results indicate that 131I therapy eliminates CSCs that survive BTZ treatment but accumulate NIS protein because of low proteasome activity.

Before performing 131I therapy in tumor-bearing mice, we first confirmed that CT26/NIS-cODC CSCs are radioiodine avid in living bodies by comparing 125I uptake after implantation in mice. Because CSCs become greatly outnumbered by differentiated cancer cells over time, imaging was performed on the day of implantation for this experiment. PET imaging confirmed high 125I uptake in CT26/NIS-cODC CSCs but not ordinary CT26/NIS-cODC cells. The accuracy of PET-based assessment of uptake was confirmed by correlation with ex vivo measured uptake. This confirmed that CT26/NIS-cODC CSCs have stabilized NIS accumulation that instigates high radioiodine uptake in living bodies.

Finally, we investigated the therapeutic capacity of the NIS-cODC system in tumor-bearing mice. Treatment with BTZ alone produced only modest growth retardation in both CT26 and CT26/NIS-cODC tumors. Addition of 131I therapy during BTZ treatment further suppressed the growth of CT26/NIS-cODC tumors but not CT26 tumors. Furthermore, tumor expression of stemness markers, which increased after treatment with BTZ alone, decreased significantly when 131I therapy was added.

In conclusion, this study demonstrates that radioiodine targeted elimination of CSCs is an efficient strategy to overcome tumor resistance to BTZ therapy. This can be accomplished by stabilization and accumulation NIS-cODC fusion protein via poor proteasome activity, which is a biologic characteristic of CSCs.

Materials and methods

Cell culture and preparation of stably expressing cell lines. CT26 mouse colon cancer cells (ATCC, #CRL-2638, USA) were maintained in RPMI (Lonza, Basel, Switzerland) supplemented with 10% fetal bovine serum (FBS; Serana, Germany) and 1% penicillin/streptomycin (Gibco Laboratories, USA) at 37 °C and 5% CO2 in a humidified atmosphere. CT26 cells that constitutively expressed NIS-cODC or ZsGreen-cODC fusion protein were prepared as previously described. Briefly, the cells were infected with pQCXIN retroviral particles containing the NIS-cODC or ZsGreen-cODC sequences, and single-cell clones with stable expression (CT26/NIS-cODC or CT26/ZsGreen-cODC cells) were selected with geneticin (Gibco Laboratories). Because the cODC sequence is a target for ubiquitin-independent degradation by the 26S proteasome, the accumulation of NIS-cODC instigates radioiodine uptake and identifies cells with poor proteasome function. Similarly, accumulation of ZsGreen-cODC identifies cells with poor proteasome activity by emitting green fluorescence. All cell lines were routinely tested for mycoplasma.

Proteasome activity assay. Cells in 6-well plates (1.2 × 106) were washed and collected by scraping with 0.5% NP-40 in distilled water. After incubation for 30 min at 20 °C and centrifugation at 13,000 rpm for 10 min at 4 °C, the proteasome activity in the supernatants was measured with a fluorometric assay kit (Bio Vision, CA). Briefly, cell extracts were mixed with 100 μl of assay buffer and 1 μl of Suc-LLVY-7-amino-4-methylcoumarin (Suc-LLVY-AMC) substrate. Fluorescence was measured at 350 nm excitation and 440 nm emission wavelengths in a microplate reader at 37 °C for 30 min. Proteasome activity was measured as the rate increase in fluorescent signals caused by Suc-LLVY-AMC degradation.

CSC enrichment through tumorsphere formation and limiting dilution assays. Cells were enriched for cancer stemness using tumorsphere formation. Briefly, cells were grown on an ultra-low attachment culture plate (Corning, NY) in CSC selection medium. The selection medium was prepared in a DMEM/F12 base that contained 0.4% bovine serum albumin, B27 supplement (Gibco Laboratories), 5 μg/ml bovine insulin, 4 μg/ml heparin, 20 ng/ml fibroblast growth factor 2, and 20 ng/ml epidermal growth factor. Tumorspheres were efficiently formed under this condition and were grown for 10 days, with fresh medium provided every 2 to 3 days. Tumorsphere-forming capacity was evaluated by limiting dilution assays. After dilution, 1, 10, 100, and 1,000 cells were seeded and cultured under the sphere formation conditions listed above. After 10 days, the number of tumorspheres was counted under a microscope.

Cellular radioiodine uptake measurement. Monolayer cells were incubated for 1 h with 74 kBq of 125I (Perkin Elmer, MA) added to the culture medium in 5% CO2 at 37 °C. Cells were rapidly washed twice with cold PBS, lysed with 0.1N NaOH, and measured for cell-bound radioactivity on a γ-counter (Wallac). Uptake levels were normalized to the protein content of each sample. For tumorsphere radioiodine uptake measurement, tumorspheres were collected and digested with trypsin-EDTA for 10 min at 37 °C. Single cells were washed and
seeded on a Matrigel-coated 24-well culture plate with RPMI medium containing 20% FBS. Control cells did not undergo tumorsphere formation but were seeded under identical conditions. 48 h after the cell seeding, the radioiodine uptake experiment was carried out as described above.

**In vitro therapy and sulforhodamine B (SRB) survival assay.** Cells on a 96-well plate were treated with BTZ (Calbiochem, MA) by adding the drug to the culture medium. For radioiodine therapy, 50 μCi or 100 μCi of 131I was added to the medium in each well, and the medium was replaced with fresh medium after 9 h of incubation at 37 °C.

The surviving cell content was measured using SRB assays. Briefly, treated and untreated cells were fixed with 10% (wt/vol) trichloroacetic acid at 4 °C and stained with SRB dye (Sigma-Aldrich) for 30 min. Excess dye was removed by repeated washing with 1% (v/v) acetic acid. Protein-bound dye was eventually dissolved in 10 mM Tris base solution and subjected to spectrophotometric measurement of absorbance at 510 nm on a microplate reader.

**Aldehyde dehydrogenase (ALDH) activity assay.** ALDH activity was measured with an Aldefluor assay kit (Stemcell Tech, BC, Canada) according to the manufacturer’s protocol. Cells were resuspended in Aldefluor assay buffer containing 1 μM Aldefluor dye. ALDH activity was blocked with 15 μM of the selective inhibitor DEAB. After incubation at 37 °C for 30 min, cells were washed with assay buffer, and 10,000 cells were analyzed on a FACS Calibur flow cytometer with CellQuest software (Becton-Dickinson, NJ).

**P-glycoprotein activity assay.** The activity of p-glycoprotein-mediated drug efflux was assessed by Efflux-ID Green assays (ENZO Life Sciences, Lörrach, Germany) following the manufacturer’s protocol. Briefly, cells harvested by trypsinization were pre-incubated for 5 min at room temperature in PBS containing 2% FBS. The buffer contained 20 μM verapamil, an MDR1 inhibitor, in DMSO or DMSO (vehicle). After Efflux-ID Green dye was added, the cells were incubated for 30 min at 37 °C. Then, 10,000 cells per sample underwent FACs analysis on a Calibur flow-cytometer using CellQuest software (Becton-Dickinson, NJ). Efflux-ID Green was excited at 490 nm, and fluorescent emissions were detected at 514 nm.

**PET imaging and radioiodine uptake measurements of implanted cancer cells.** Before performing murine tumor model experiments, we evaluated whether stem-like cancer cells absorbed increased radioiodine in living bodies. For this experiment, CT26/NIS-cODC cells were prepared by trypsinization of tumorspheres followed by the stabilization of cells in culture medium at 37 °C for 30 min before implantation. Normal BALB/c male 5 weeks aged mice (Orient bio, Korea) who had not received BTZ treatment (n = 4) were injected with cells with and without CSC enrichment on the right and left thigh, respectively. After 30 min, the animals were injected with 13.0 MBq of 124I, and PET/CT images were acquired 1 h later. Quantitative analysis of the radioiodine uptake on PET images was performed using the tumor-to-background (shoulder region) ratio as an index of uptake.

Immediately after PET imaging, the animals were sacrificed by cervical dislocation, and thigh tissue injected with tumor cells and shoulder tissue were extracted, weighed, and measured for 124I activity. For ex vivo quantification, 124I counts attributable to cancer cells were calculated using the following formula. Counts from cancer cells = total thigh tissue counts—background tissue counts. The latter was estimated from shoulder tissue counts corrected for weight (the thigh-to-shoulder muscle weight ratio). The resulting count from cancer cells per weight of target tissue was finally divided by the count per weight of shoulder tissue to obtain the relative radioactive count ratio as an index of cancer cell uptake.

This experiment was repeated in a separate group of 5 week-old normal male BALB/c mice (n = 4) under the same conditions but using 131I instead of 124I. Cells were prepared and injected into thigh muscles of the mice and 131I of 5.5 MBq was intravenously injected 30 min later. Tissues were then extracted, weighed, and 131I attributable to cancer cells were calculated as above.

**Mouse xenograft model and treatment.** Tumor models were prepared in BALB/c male 5 weeks aged mice (Orient bio, Korea) by subcutaneous injection of 3.2 × 10⁶ non-transformed CT26 cells or CT26/NIS-cODC cells into the right shoulder region. After 4 days, animals with early tumors of similar sizes were randomly divided into treatment groups: DMSO vehicle group (n = 3 for CT26; n = 7 for CT26/NIS-cODC), 131I alone group (n = 8 for CT26/NIS-cODC), BTZ alone group (n = 4 for CT26; n = 7 for CT26/NIS-cODC), and BTZ plus 131I treatment group (n = 4 for CT26; n = 8 for CT26/NIS-cODC). BTZ was intraperitoneally injected (2 mg/kg) three times per week for 28 days. 131I treatment was given as a single 800 μCi dose by intravenous injection 11 days after cancer cell injection. Mice were assessed for body weight and tumor size at the time of each BTZ treatment. After the end of treatment, the mice were sacrificed by cervical dislocation. Tumor tissues were excised, and the weight of the mice after tumor removal was measured. All animal experiments were in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals and approved by the appropriate institutional committee.

**Immunoblotting.** Immunoblotting was performed as previously described. Cultured cells and tumor tissues were lysed with cold protein extraction solution (PRO-PREP; Intron, Korea) and T-PER tissue protein extraction solution (Thermo Fisher Scientific), respectively, that contained a protease inhibitor cocktail (Sigma Aldrich). After protein assays, 30 μg of samples were separated by electrophoresis on a 10% sodium dodecyl sulfate polyacrylamide gel, followed by transfer to a polyvinylidene difluoride membrane. The membrane was
Immunohistochemistry staining. Immunohistochemistry staining of formalin-fixed and paraffin-embedded tissues was performed as previously described. After micro-sectioning at 4 µm thickness, the sections underwent heat-induced antigen retrieval for 3 min in EDTA buffer (pH 9.0; Dako, Carpinteria, CA). Sectioned slides were then incubated overnight with anti-human NIS (1:100 dilution; Santa Cruz Biotechnology, #sc-134515) at 4 °C. This was followed by incubation with HRP-labeled polymer-conjugated secondary antibodies against rabbit IgG (Dako) for 30 min at room temperature. A color reaction was induced using a ready-to-use 3,3′-diaminobenzidine substrate-chromogen solution (Dako) for 5 min, followed by washing with distilled water. Finally, sections were lightly counterstained with Mayer’s hematoxylin for 30 s before dehydration and mounting.

Statistical analysis. Data are presented as the mean ± SD. The significance of differences between groups was analyzed by two-tailed unpaired student’s t-tests for two groups and ANOVA with Tukey’s post-hoc tests for three or more groups. P values <0.05 were considered statistically significant.

Ethical approval. All animal experiments were performed according to the National Institutes of Health Guide for Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of Samsung Medical Center.

Data availability
All data generated or analyzed during this study are included in this published article.

Received: 18 February 2020; Accepted: 6 July 2020
Published online: 31 August 2020

References
1. Hussain, S. et al. Cancer drug resistance: a fleet to conquer. J. Cell Biochem. 120, 14213–14225 (2019).
2. Dean, M. Cancer stem cells: implications for cancer causation and therapy resistance. Discov. Med. 5, 278–282 (2005).
3. Steinbichler, T. B. et al. Therapy resistance mediated by cancer stem cells. Semin. Cancer Biol. 53, 156–167 (2018).
4. Lee, M. C. et al. Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing. Proc. Natl. Acad. Sci. USA 111, E4726–E4735 (2014).
5. Kurtova, A. V. et al. Blocking PGE2-induced tumor repopulation abrogates bladder cancer chemoresistance. Nature 517, 209–213 (2015).
6. Kim, C. et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell 173, 879–893 (2018).
7. Hata, A. N. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262–269 (2016).
8. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105–111 (2001).
9. Dobbelsleim, M. & Moll, U. Targeting tumour-supportive cellular machineries in anticancer drug development. Nat. Rev. Drug Discov. 13, 179–196 (2014).
10. Chen, L. & Madura, K. Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res. 65, 5599–5606 (2005).
11. Loda, M. et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 3, 231–234 (1997).
12. Oren, M. & Kotler, E. p53 mutations promote protaesomal activity. Nat. Cell Biol. 18, 833–835 (2016).
13. Nalepa, G., Rolfe, M. & Harper, J. W. Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discov. 5, 396–613 (2006).
14. Adams, J. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 4, 349–360 (2004).
15. Robak, T. et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N. Engl. J. Med. 372, 944–953 (2015).
16. Richardson, P. G. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 345, 2609–2617 (2003).
17. Roeten, M. S. F., Cloos, J. & Jansen, G. Positioning of proteasome inhibitors in therapy of solid malignancies. Cancer Chemother. Pharmacol. 81, 227–243 (2018).
18. Kirshner, I. et al. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood 112, 2935–2945 (2008).
19. Voutsadakis, I. A. Proteasome expression and activity in cancer and cancer stem cells. Tumour Biol. 39, 1010428317692248 (2017).
20. Lagadec, C. et al. Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients. BMC Cancer 14, 152 (2014).
21. Lagadec, C. et al. Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res. 12, R13 (2010).
22. Pan, J., Zhang, Q., Wang, Y. & You, M. 26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro. PLoS ONE 5, e13298 (2010).
23. Vlashi, E. et al. In vivo imaging, tracking, and targeting of cancer stem cells. J. Natl. Cancer Inst. 101, 350–359 (2009).
24. Vlashi, E. et al. Targeted elimination of breast cancer cells with low proteasome activity is sufficient for tumor regression. Breast Cancer Res Treat. 141, 197–203 (2013).
25. Lenos, K. J. & Vermeulen, L. Cancer stem cells don’t waste their time cleaning-low proteasome activity, a marker for cancer stem cell function. Ann. Transl. Med. 4, 519 (2016).
26. Lee, J. H. et al. Reporter PET images Bortezomib treatment-mediated suppression of cancer cell proteasome activity. *Sci. Rep.* **8**, 12290 (2018).
27. Paldino, E., Tesori, V., Casalbore, P., Gasbarrini, A. & Puglisi, M. A. Tumor initiating cells and chemoresistance: which is the best strategy to target colon cancer stem cells?. *Biomed. Res. Int.* **2014**, 859871 (2014).
28. Kozovska, Z., Gabrisova, V. & Kucerova, L. Colon cancer: cancer stem cells markers, drug resistance and treatment. *Biomed. Pharmacother.* **68**, 911–916 (2014).
29. Kreus, A. et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. *Science* **339**, 543–548 (2013).
30. O’Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature* **445**, 106–110 (2007).
31. Yeung, T. M., Gandhi, S. C., Wilding, J. L., Muschel, R. & Bodmer, W. F. Cancer stem cells from colorectal cancer-derived cell lines. *Proc. Natl. Acad. Sci. USA* **107**, 3722–3727 (2010).
32. Adikrisna, R. et al. Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents. *Gastroenterology* **143**, 234–245 (2012).
33. Donna, D. L., Lagadec, C. & Pajonk, F. Radioresistance of prostate cancer cells with low proteasome activity. *Prostate* **72**, 868–874 (2012).
34. Hayashi, K. et al. Visualization and characterization of cancer stem-like cells in cervical cancer. *Int. J. Oncol.* **45**, 2468–2474 (2014).
35. Stacer, A. C. et al. Imaging reporters for proteasome activity identify tumor- and metastasis-initiating cells. *Mol. Imaging* **14**, 414–428 (2015).
36. Lagadec, C. et al. The RNA-binding protein Musashi-1 regulates proteasome subunit expression in breast cancer- and glioma-initiating cells. *Stem Cells* **32**, 135–144 (2014).
37. Tamari, K. et al. Identification of chemoradiation-resistant osteosarcoma stem cells using an imaging system for proteasome activity. *Int. J. Oncol.* **45**, 2349–2354 (2014).
38. Munakata, K. et al. Cancer stem-like properties in colorectal cancer cells with low proteasome activity. *Clin. Cancer Res.* **22**, 5277–5286 (2016).
39. Song, J., Chang, I., Chen, Z., Kang, M. & Wang, C. Y. Characterization of side populations in HNSCC: highly invasive, chemoresistant and abnormal Wnt signaling. *PLoS ONE* **5**, e11456 (2010).
40. Giuffrida, R. et al. Resistance of papillary thyroid cancer stem cells to chemotherapy. *Oncol. Lett.* **12**, 687–691 (2016).
41. Vichai, V. & Kirtikara, K. Sulforhodamine B colorimetric assay for cytotoxicity screening. *Nat. Protoc.* **5**, 1112–1116 (2006).
42. Armstrong, L. et al. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. *Stem Cells* **22**, 1142–1151 (2004).
43. Park, J. W. et al. Imaging early fate of cancer stem cells in mouse hindlimbs with sodium iodide symporter gene and I-124 PET. *Mol. Imaging Biol.* **18**, 748–757 (2016).
44. Kim, Y. S., Kaidina, A. M., Chiang, J. H., Yarygin, K. N. & Lupatov, A. Y. Cancer stem cell molecular markers verified in vivo. *Biochem. Moscow Suppl. Ser. B* **11**, 43–54 (2017).
45. Armstrong, L. et al. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. *Stem Cells* **22**, 1142–1151 (2004).
46. Park, J. W. et al. Imaging early fate of cancer stem cells in mouse hindlimbs with sodium iodide symporter gene and I-124 PET. *Mol. Imaging Biol.* **18**, 748–757 (2016).
47. Jung, K. H., Paik, J. Y., Ko, B. H. & Lee, K. H. Mitogen-activated protein kinase signaling enhances sodium iodide symporter function and efficacy of radiosensitizer therapy in nonthyroidal cancer cells. *J. Nucl. Med.* **49**, 1966–1972 (2008).
48. Vichai, V. & Kirtikara, K. Sulfurhodamine B colorimetric assay for cytotoxicity screening. *Nat. Protoc.* **1**, 1112–1116 (2006).
49. Park, J. W. et al. ATP-binding cassette transporters substantially reduce estimates of ALDH-positive cancer cells based on aldefluor and AldeRed588 assays. *Sci. Rep.* **9**, 6462 (2019).
50. Lebedeva, I. V., Pande, P. & Patton, W. F. Sensitive and specific functional probes for functional analysis of the three major types of mammalian ABC transporters. *PLoS ONE* **6**, e22429. https://doi.org/10.1371/journal.pone.0022429 (2011).

Acknowledgements

This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2019R1A2C2007455).

Author contributions

K.H.L. and J.H.L. designed the experiments and analyzed the data. J.H.L., J.W.P., and K.H.J. carried out the experiments. K.H.L., J.H.L., and K.H.J. interpreted the data. S.H.M and Y.S.C. performed the image analyses. K.H.L. and J.H.L. wrote the manuscript. All authors read, provided feedback on, and approved the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-71366-3.

Correspondence and requests for materials should be addressed to K.-H.L.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020